Avalo Therapeutics AVTX Total costs & expenses
Total costs & expenses at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CostsAndExpenses.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's total costs & expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's total costs & expenses?
- Avalo Therapeutics (AVTX) reported total costs & expenses of $20.9M in Q1 2026.
- How has Avalo Therapeutics's total costs & expenses changed year-over-year?
- Avalo Therapeutics's total costs & expenses increased by 42.5% year-over-year, from $14.67M to $20.9M.
- What is the long-term trend for Avalo Therapeutics's total costs & expenses?
- Over 4 years (2021 to 2025), Avalo Therapeutics's total costs & expenses has grown at a -4.4% compound annual growth rate (CAGR), from $87.53M to $72.98M.
- What does total costs & expenses mean?
- The aggregate sum of all operating and non-operating costs incurred by the company to sustain its business operations, including research, development, and administrative functions. This metric serves as a primary indicator of the company's overall burn rate and operational scale. It is essential for evaluating the company's cost structure and the efficiency with which it manages resources to achieve clinical milestones.